Navigation Links
Micromet's Blinatumomab Induces Durable Remissions in Patients with Relapsed Non-Hodgkin's Lymphoma
Date:6/14/2010

BETHESDA, Md., June 14 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced the presentation of updated results from a Phase 1 trial of the Company's lead product candidate blinatumomab (MT103) in patients with relapsed non-Hodgkin's lymphoma (NHL).  A high objective response rate was maintained among patients treated with blinatumomab using an adapted schedule, comparable to that previously reported in patients receiving constant dosing.  Blinatumomab is the first in a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells.

The findings were presented on June 12, 2010 in an oral presentation (abstract # 0559) at the 15th Annual Congress of the European Hematology Association (EHA) in Barcelona, Spain.

"Blinatumomab continues to demonstrate a long duration of response in heavily pre-treated non-Hodgkin's lymphoma patients," said Professor Ralph Bargou, Division of Hematology and Oncology, Department of Internal Medicine II, Wuerzburg University Hospital, and the study's principal investigator. "Results of the expanded Phase 1 experience suggest that blinatumomab has the potential to alter the clinical course of disease in patients with a variety of NHL sub-types."

Phase 1 Study Design

This multi-center Phase 1 study evaluates the safety and tolerability of blinatumomab in adult patients with relapsed non-Hodgkin's lymphoma (NHL).  The key objectives of the study are to assess safety and tolerability, pharmacokinetics, pharmacodynamics, and anti-lymphoma activity. &#
'/>"/>

SOURCE Micromet, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Micromet Highlights Clinical Plans and Regulatory Strategy for Lead Product Candidate Blinatumomab at its Annual R&D Day
2. Final Data from Phase 2 Study Confirm High Response Rate of Micromets Blinatumomab in Patients with Acute Lymphoblastic Leukemia
3. Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
4. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
5. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
6. Clinical Data Published in Science Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab
7. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
8. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
9. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
10. Video: Resveratrol-based Nutriceutical (Longevinex(R)) Induces Favorable Changes on Gene Expression in Mouse Heart At Doses 17-320 Times Lower Than Prior Studies
11. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Calif. , Dec. 19, 2014  Newport ... that Siddhartha Kadia, Ph.D. has joined the company,s ... Chief Executive Officer and a director of Evans ... laboratory testing, evaluation and analytical services to companies ... Prior to joining Evans Analytical Group, Dr. ...
(Date:12/19/2014)... HILL, N.C. , Dec. 19, 2014 /PRNewswire/ ... to optimize a product,s web presence to reflect ... Brand websites, in particular, must meet the needs ... regulations and culture. According to ... more than half of the participating companies averaged ...
(Date:12/19/2014)... Somewhere between dropping five pounds and cooking ... Audicus , a next-generation hearing aids company, will ... Hearing loss is the third most common ... is often unaddressed. Forty-eight million Americans have hearing loss, ... mainly due to price. Hearing aids traditionally cost $7,000 ...
Breaking Medicine Technology:Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2Building a Best-in-Class Pharma Global Brand Website 2Audicus Will Help People Resolve to Hear Better in 2015 2
(Date:12/22/2014)... Explorys, the leader in big data-driven ... team: Greg Yarrington as Vice President of Operations, Adam ... as Vice President of Solutions. These new leaders are ... in 2015 to support client demand for the company’s ... and growth of its partner network. , Since ...
(Date:12/22/2014)... 22, 2014 Pasadena sleep apnea ... for sleep apnea. Drowsy drivers are 15 times more ... are well-rested, and some experts believe that sleep-deprived drivers ... intoxicated drivers. Unfortunately, millions of Americans may be sleep-deprived ... of Sleep Medicine, about 18 million Americans have sleep ...
(Date:12/22/2014)... Christmas is days away, and last minute ... easy solution that will please: the Sublime Gift Card ... from $25 up to $350," says Kathy Heshelow, founder of ... a wide array of skin care products and Skin Brushes." ... dates. , Gift delivery past shipping deadlines, or those ...
(Date:12/22/2014)... At the annual National ... in San Antonio, esteemed experts and thought leaders ... stand in the way of successful organizational performance: ... premier faculty development opportunity is made possible through ... is to assist nurse educators to advance to ...
(Date:12/21/2014)... offers a wide range of women’s dresses, fashionable accessories ... BellasDress Christmas Sale , offering big discounts on all ... a famous online supplier of women’s dresses; it always ... promotions. The dress experts of the company provide professional ... of offering high quality wedding dresses and women’s special ...
Breaking Medicine News(10 mins):Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 3Health News:BellasDress.com Announces its BellasDress Christmas Sale 2
... 30 Thoratec,Corporation (Nasdaq: THOR ), a ... today that the FDA Circulatory System Devices,Advisory Panel ... the company,s PMA (PreMarket Approval) allowing the use ... as a,bridge-to-transplantation (BTT)., The HeartMate II is ...
... Families with Deployed Service Members ... ... to Operation Cares, which supports the needs of the,more than 4,000 of South ... the central market area at,TriWest, will present the check to Steve Doohen, secretary ...
... cell agency is inviting for-profit companies to apply ... for Taxpayer and Consumer Rights,(FTCR) noted today and ... the awards process to prevent abuse., The ... calls for applications for two types of grants. ...
... following is a,statement from Henrietta H. Fore, USAID ... again recognizes World AIDS,Day and the more than ... Through the President,s Emergency Plan for AIDS Relief ... supporting those,battling the disease, as well as those ...
... ALEXANDRIA, Va., Nov. 30 The Pharmaceutical,Care ... falsely claiming,that pending legislation requiring prompt payment ... cost billions of dollars. PCMA represents 10,pharmacy ... administer,prescription drug plans. In response, Bruce Roberts, ...
... Neurochem Inc. (NASDAQ:,NRMX; TSX: NRM) today announces the ... Business. Dr. Calais joined Neurochem,in 2003, and is ... "Dr. Calais has made a significant contribution ... and we,are grateful for having had the benefit ...
Cached Medicine News:Health News:Thoratec Announces Unanimous FDA Advisory Panel Recommendation for Approval of HeartMate II(R) for Bridge-to-Transplantation 2Health News:Thoratec Announces Unanimous FDA Advisory Panel Recommendation for Approval of HeartMate II(R) for Bridge-to-Transplantation 3Health News:TriWest Contributes $10,000 to Operation Cares for South Dakota's Military Families 2Health News:Close Scrutiny Needed as First Stem Cell Grants Offered to For-Profit Companies, Consumers Say 2Health News:On World AIDS Day, Keeping the Promise to Stop AIDS Through the Power of Partnerships 2Health News:NCPA Statement on Bogus PCMA Study About Cost to Fix Medicare Part D 2Health News:Neurochem announces departure of Dr. Philippe Calais, President, Global Business 2
This flexiable metal clip-on easily attaches to most frames and allows for excellent radiation protection. Not available with side shields or in prescription....
All New Ultra Pb Series Glasses...
... eye protection Properly manufactured radiation protective ... radiation. Our high quality frames and materials ... minimized weight. Our lenses are made of ... all industry standards. Most Pulse Glasses are ...
... Stylish and comfortable eye protection ... approximately 90% of scatter radiation. Our high ... protection and comfort with minimized weight. Our ... leaded) optics that meet all industry standards. ...
Medicine Products: